Browse drugs

… points; 95% confidence interval [CI], 12.5 to 33.6; P<0.0001). Obinutuzumab was superior to placebo with statistically significant benefit …

…ies rendering it capable of superior B-cell killing compared to rituximab.5 The NOBILITY trial, a phase 2 clinical trial in patients with…

…ods A retrospective analysis included SLE patients treated with belimumab (n=25), obinutuzumab (n=8), and voclosporin (n=3) for >=6 month…

…es The REGENCY trial ( NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achie…

…renal response at Week 76, with a manageable safety profile for obinutuzumab. This study aimed to further characterise the occurrence of ser…

…H, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–28. doi: 10…

…M, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results fro…

…nd plasma exchange was given without efficacy so treatment with obinutuzumab plus cyclophosphamide was initiated, with gradual neurological …

…omitant immunosuppressive biologics in LN patients treated with voclosporin. This is notable given the unique and possibly synergistic effe…

…b in 25, belimumab in 16, obinutuzumab in 2, voclosporin in 21, tacrolimus in 6, cyclosporin-A in 4 and azathioprine in 3 patients. Six pa…

…sant; 3/5 rituximab and 4/5 belimumab. Concomitant therapy: 5/5 hydroxychloroquine, 4/5 MMF/Na, 5/5 prednisone (mean baseline dose 15 mg/day (10-1…

…20 monoclonal antibody that has demonstrated its superiority to rituximab (RTX) in vitro and in vivo. Our assumption is that a single inf…